Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants-Reference-Cited by-同舟云学术

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

Published:2016-04-12 Issue:22 Volume:7 Page:32318-32328
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Chowdhury Subrata¹,Veyhl Joe¹,Jessa Fatima¹,Polyakova Olena¹²,Alenzi Ahmed¹²,MacMillan Christina³⁴,Ralhan Ranju¹⁵³⁴⁶,Walfish Paul G.¹⁵³⁴²

Affiliation:

1. Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada

2. Department of Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto Medical School, Toronto, Ontario, Canada

3. Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

4. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

5. Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Department of Otolaryngology-Head and Neck Surgery Program, Mount Sinai Hospital, Toronto, Ontario, Canada

6. Department of Otolaryngology-Head and Neck Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1;RSC Medicinal Chemistry;2024

2. Harnessing Immunity to Treat Advanced Thyroid Cancer;Vaccines;2023-12-30

3. The features of PD-L1 expression in tumor stromal cells, peritumoral microvessels and isolated clusters of tumor cells in breast cancer tissue and their correlation with clinical and morphological characteristics of breast cancer;Siberian journal of oncology;2023-11-15

4. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression;Journal for ImmunoTherapy of Cancer;2023-11

5. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas;Pathology - Research and Practice;2023-10